In conclusion, we showed that molecular imaging, with its noninvasiveness and ability to evaluate the entire disease burden, can assess HER2 heterogeneity in HER2-positive breast cancer and can predict very early on lesions and patients not responding to the “parent” antibody-drug conjugate T-DM1. This evidence concerns the gene ERBB2 and breast carcinoma.